The mechanisms by which arterial fate is established and maintained are not clearly understood. Although a number of signaling pathways and transcriptional regulators have been implicated in arterio-venous differentiation, none are essential for arterial formation, and the manner in which widely expressed factors may achieve arterial-specific gene regulation is unclear. Using both mouse and zebrafish models, we demonstrate here that arterial specification is regulated combinatorially by Notch signaling and SoxF transcription factors, via direct transcriptional gene activation. Through the identification and characterization of two arterial endothelial cell-specific gene enhancers for the Notch ligand Delta-like ligand 4 (Dll4), we show that arterial Dll4 expression requires the direct binding of both the RBPJ/Notch intracellular domain and SOXF transcription factors. Specific combinatorial, but not individual, loss of SOXF and RBPJ DNA binding ablates all Dll4 enhancer-transgene expression despite the presence of multiple functional ETS binding sites, as does knockdown of sox7; sox18 in combination with loss of Notch signaling. Furthermore, triple knockdown of sox7, sox18 and rbpj also results in ablation of endogenous dll4 expression. Fascinatingly, this combinatorial ablation leads to a loss of arterial markers and the absence of a detectable dorsal aorta, demonstrating the essential roles of SoxF and Notch, together, in the acquisition of arterial identity.
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arterial-specific enhancer | CSL E ndothelial cell commitment to an arterial or venous fate during development, once thought to be primarily determined by physiological cues, is now known to be mediated by the specific expression of genes, including those encoding ligands, receptors, and transcription factors (1) . The endothelialexpressed SOXF subfamily of transcription factors has been implicated in this process. Similar to other SOX proteins, SOXF factors directly bind the core DNA sequence WWCAAW (2, 3) . In zebrafish, sox7 and sox18 are expressed in both the dorsal aorta and posterior cardinal vein during early development whereas zebrafish sox17 is not vascular (4, 5) . Combined knockdown of sox7 and sox18 results in fusions between axial vessels and in down-regulation, but not loss, of arterial markers, including dll4 (4) (5) (6) . In mammals, all three SOXF proteins are expressed in the developing aorta (7) . However, expression is also detected in some veins, and Sox18 plays an additional role in early lymphatic vessel differentiation (7) (8) (9) . Functional redundancy, overlapping expression, and a lack of direct gene targets has meant that the role of SOXF proteins in mammals is unclear, and their lack of specificity within the vasculature suggests that they act in synergy with other, yet to be identified factors (6, 8) .
The Notch signaling pathway also plays a key role in arteriovenous differentiation, where most components of the Notch pathway are specific to arteries (10, 11) . Activation of Notch receptor after ligand binding results in the translocation of Notch intracellular domain (NICD) to the nucleus, where it engages the DNA-binding factor RBPJ (CSL) and coactivator Mastermind to form an activation complex (10) . Loss of Notch signaling in zebrafish results in defective arterial-venous differentiation although a distinct dorsal aorta still forms, and some arterialspecific genes are expressed (10) . Mice null for the Notch1 and -4 receptors also display severe vascular remodeling defects, as do those lacking Rbpj and Delta-like ligand 4 (Dll4), the arterial-specific Notch ligand (12) (13) (14) . Loss of VEGF signaling in fish can be rescued by activation of Notch signaling, suggesting that Notch is downstream of VEGF in a common genetic pathway (15) . However, VEGF inhibition results in more severe vascular defects, and arterial genes display differential sensitivity to Notch and VEGF signaling (10, 15) . It is therefore likely that additional, currently unidentified factors contribute to arterial differentiation downstream of VEGF.
Spatiotemporal regulation of gene transcription during development is primarily accomplished by enhancers, although those located close to core promoters are also often termed proximal promoters (16) . Investigation of endothelial enhancers, coupled with the analysis of mutant animal models, has demonstrated the essential role of the ETS transcription factor family during early endothelial cell specification and development (17, 18) . However, the transcriptional cascades regulating the differentiation of endothelial cells are less well understood. Few direct transcriptional targets of Notch have been identified in arterial endothelial cells, and the mechanisms regulating the expression of Notch components and other arterial-specific genes are poorly understood.
Results
Identification of an Arterial Endothelial Cell-Specific Enhancer Within the Third Intron of the Dll4 Gene. An in silico search of the Dll4 locus for regions enriched in human umbilical vein endothelial cells (HUVEC)-specific H3K27Ac histone modification, associated with active enhancer regions (19) , identified the highly conserved third intron of Dll4 (Dll4in3) as a putative enhancer (Fig. S1A) . A 937-bp fragment containing the mouse Dll4in3 region was cloned upstream of the silent hsp68 minimal promoter-β-galactosidase (LacZ) reporter gene (Dll4in3hsp) or the endogenous Dll4 promoter-LacZ reporter gene (Dll4in3end) (Fig. 1A and Fig. S1B ). Mice transgenic for both Dll4in3end and Dll4in3hsp expressed the LacZ reporter gene in arterial but not venous endothelial cells throughout embryonic development and postnatally, mimicking the expression pattern of endogenous Dll4 (20) (Fig. 1 B-L , and Fig. S1 C-O) . The Dll4in3 enhancer was also able to drive arterial-specific expression in transgenic zebrafish. The 937-bp mouse Dll4in3 sequence, in conjunction with the E1b minimal promoter (21) and GFP reporter gene, was used to generate the stable transgenic zebrafish line tg(Dll4in3: GFP) (Fig. 1M) . As in transgenic mice, reporter gene expression in tg(Dll4in3:GFP) embryos was detected in arteries (including the dorsal aorta), but not in veins ( Fig. 1 N and O and Fig. S1P) . These results clearly demonstrate that the Dll4in3 enhancer contains sufficient information to direct arterial endothelial cellspecific expression during embryonic development, independent of the endogenous promoter.
The Dll4in3 enhancer is deeply conserved throughout vertebrate evolution, and the orthologous zebrafish region could be clearly identified, although only a small part of the intronic sequences shared notable sequence conservation (Fig. S1A) . To establish whether the information directing arterial-specific expression of Dll4in3 was functionally conserved between mouse and zebrafish, we generated mice transgenic for a 699-bp zebrafish sequence including Dll4 intron 3 (zfishDll4in3) upstream of hsp68-LacZ (Fig. 1P ). The zebrafish enhancer was able to direct an arterial endothelial cell-specific expression pattern in a manner similar to mouse Dll4in3hsp ( Fig. 1 Q-U) , suggesting that sequence motifs conserved within both enhancers play key roles in arterial specification.
Dll4in3 Enhancer Is Bound and Regulated by a Combination of SOXF
and RBPJ Transcription Factors. The sequences conserved between the mouse and zebrafish Dll4in3 enhancers were investigated using ClustalW (22) to identify putative transcription factor binding motifs, which were then verified by electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) ( Fig. 2A, Fig. S2 ). Binding sites for SOXF (sites a and b), RBPJ (site a), and MEF2C, TBX, and ETS (sites a, b, g, and h) were identified and confirmed ( Fig. S2 A-C). Additional sites for ETS (sites c, d, e, and f), FOXC, and RBPJ (site b) showed no detectable binding in EMSA ( Fig. S2 C and D) . To determine which motifs contributed to arterial expression, we generated a series of modified enhancers in which individual binding motifs were destroyed through sequence mutation or deletion (exact sequences of mutations and deletions are provided in SI Materials and Methods). These constructs were then used to generate Tol2-mediated mosaic transient transgenic zebrafish, and GFP expression in the fish vasculature was assessed at 24 hours postfertilization (hpf) (Fig. 2B and Fig. S3 ). Unsurprisingly, in light of the known role of ETS factors in early endothelial development (20) , mutation of the functional ETS binding motifs resulted in near-total ablation of Dll4in3 expression ( Fig. 2B and Fig. S3C ). ETS proteins are expressed in both veins and arteries, and ETS binding motifs are required elements in all known vascular enhancers (18) . Consequently, we hypothesized that alternative transcription factors may contribute to arterial-specific Dll4in3 expression. Surprisingly, however, alterations affecting binding to any other single cis-motif within the Dll4in3 enhancer did not result in a significant loss of expression in the transgenic fish assay ( To ensure that these observations were not specific to the fish model, and to more clearly examine the expression pattern of mutated transgenes within the vasculature, the same modified enhancers were tested in transgenic mice ( Fig. 2 C-F, Fig. S4 , and Table S1 ). Because FOXC transcription factors have been reported to regulate Dll4 expression (23), we also mutated the putative FOXC binding motif although we found no evidence of FOXC biding in EMSA (Fig. S2C) . As in zebrafish, ablation of protein binding to any individual motif, including FOXC, had no detectable effect on arterial-specific expression of the reporter in mice (Fig. 2 C-F, Fig. S4 ). Mutating the RBPJ-a site in combination with the RBPJ-b site (which did not bind in EMSA analysis) also had no detectable effect on arterial-specific expression (Fig. 2C, Fig. S4 ). However, mutation of SOX-a combined with deletion of SOX-b resulted in reduced vascular expression although arterial specificity was still observed (Fig. 2G) . Similar results were seen after combined mutation of SOX-a and RBPJ-a motifs (Fig. 2H ). More interestingly, ablation of both SOXF-a and -b in combination with the RBPJ-a mutation resulted in a total absence of transgene expression in arteries, in both embryonic day (E) 11 and E9 transgenic embryos (Fig.  2 C, I , and J and Fig. S4) , and a near-absolute silencing of the enhancer transgene in transgenic fish (Fig. 2B and Fig. S3J ). Because SOXF factors are known to interact with MEF2, care was taken to confirm that the RBPJ-a mutation did not alter the binding of MEF2C (Fig. S2C, lane 9) . These results suggest that RBPJ and SOXF transcription factors combinatorially regulate Dll4 arterial expression through direct DNA binding at the Dll4in3 enhancer.
Second Dll4 Arterial Enhancer Is also Regulated by SOX and RBPJ. It is now well established that dynamically expressed genes often contain multiple enhancers, some of which direct overlapping, or at least very similar, patterns of expression. This phenomenon has been reported for a number of endothelial-expressed genes, including Mef2c, Tal1, and Kdr (18, 24) . Some arterial β-gal expression is detectable in Dll4
LacZ/+ mice, where a region including the Dll4in3 enhancer was replaced by LacZ (14) , suggesting that the Dll4 gene was under the regulation of additional endothelial enhancers present somewhere else. Because the 51-kb Dll4 locus contained four peaks of HUVEC-specific H3K27Ac (Fig. S1A) , we tested the remaining three peaks (−16, −12, and +14) upstream of the hsp68 minimal promoter and LacZ reporter gene in transgenic mice. Although Dll4-16hsp and Dll4+14hsp were unable to direct expression in endothelial cells, the 857-bp Dll4−12 enhancer directed arterial endothelialspecific expression in a pattern similar to Dll4in3 (Fig. 3 A-C,  Fig. S5 A and B) although it was not conserved in zebrafish, nor able to drive expression in transgenic zebrafish. Analysis of Dll4-12 identified two functional SOX sites and one RBPJ site (Fig.  S5 C-E) . A mutant Dll4-12 enhancer lacking functional versions of these sites (SI Materials and Methods) was no longer able to direct transgene expression to the arterial compartment (Fig. 3 D  and E) , further demonstrating the key roles of SOXF and RBPJ in Dll4 gene regulation during embryonic development.
Both SOXF and RBPJ Factors Are Required for Arterial Development.
We next examined the consequences of morpholino (MO) knockdown of the orthologous genes sox7, sox18, and rbpj in WT and tg(Dll4in3:GFP) zebrafish embryos. All MOs used were validated in previous studies (SI Materials and Methods). MOinduced knockdown of rbpj had little effect on the expression of either Dll4in3:GFP or endogenous dll4 although the known hypersprouting phenotype was clearly detectable (Fig. 4, Fig. S6A ) (25) . The double sox7;sox18 MO led to diminished, but still detectable, expression of GFP in tg(Dll4in3:GFP) embryos, with similar reductions in endogenous dll4 levels, agreeing with previous studies (Fig. 4B, Fig. S6A ) (6) . Remarkably, triple sox7; sox18;rbpj MO resulted in complete silencing of GFP expression in tg(Dll4in3:GFP) fish, with cognate near-total ablation of endogenous dll4 expression in the vasculature (Fig. 4 A and B, Fig.  S6 ). Inhibition of NICD translocation to the nucleus by treating tg(Dll4in3:GFP) embryos with the γ-secretase inhibitor N-[N-3,5-Difluorophenacetyl]-L-alanyl-S-phenylglycine Methyl Ester (DAPM) exactly recapitulated the results obtained with the rbpj MO (Fig. S6 B-E) . Furthermore, chemical inhibition of the VEGF pathway resulted in total loss of Dll4in3:GFP expression, alone and in combination with rbpj and sox7;sox18 MOs (Fig. S6 F-I) . These results indicate that Notch and SoxF factors combinatorially regulate Dll4 expression in arteries downstream of VEGF.
To more accurately understand the phenotypic effects of triple sox7;sox18;rpbj knockdown, we investigated the expression pattern of the pan-vascular marker fli1a after MO injections (26) . Triple sox7;sox18;rbpj MO did not result in notable reductions in GFP levels in tg(Fli1a:GFP) embryos, nor of endogenous fli1a (Fig. 5 A and B and Fig. S7 A and B) , suggesting that the loss of dll4 expression observed in Fig.4 was not due to a total absence of vasculature, and indicating that fli1a was not a downstream target of the soxF/rbpj code. Indeed, analysis of early zebrafish embryos revealed that triple sox7;sox18;rbpj MO did not affect the assembly of angioblasts at the posterior lateral mesoderm, nor the coalescence of these angioblasts at the midline to form a single vascular cord (Fig. 5A) . However, by 26 hpf, tg(Fli1a: GFP) embryos injected with control MO displayed a detectable dorsal aorta and cardinal veins whereas triple sox7;sox18;rbpj MO embryos had only one discernible axial vessel, suggesting a defect in arterio-venous segregation (Fig. 5, Fig. S7B ) (27) . In addition, no evidence of increased apoptosis was detected (Fig.  S7 C and D) . These morphological differences persisted at 48 hpf ( Fig. 5B and Movies S1, S2, S3, and S4). In agreement with previous reports, rbpj or sox7;sox18 MOs injected separately resulted in an intermediate phenotype in which a dorsal aorta and cardinal vein could still be seen (Fig. 5B and Fig. S7B ) (4) (5) (6) 10) . Examination of tg(kdrl:GFP);tg(gata1:dsRed) embryos 48 hpf after triple sox7;sox18;rbpj MO further confirmed the phenotype whereas gata1:dsRed expression patterns demonstrated the loss of blood flow in triple MO embryos (Fig. S7E) . Interestingly, sprouting of intersegmental vessels, although retarded, was still detected at 48 hpf in both tg(fli1a:GFP) and tg(kdrl:GFP) embryos after triple sox7;sox18;rbpj MO-injection. Although this sprouting may be a consequence of MO dilution during development, efnb2a MO-injected embryos, unable to form a distinct dorsal aorta, also form intersegmental vessels (27) .
These observations, combined with the loss of dll4 expression seen in Fig.4 , suggest that, whereas angioblast formation and migration are unaffected by triple sox7;sox18;rbpj MO, endothelial cells do not take on an arterial identity and the dorsal aorta fails to form. Therefore, we looked at the expression of markers of venous and arterial differentiation in zebrafish after control, single rbpj, double sox7;sox18, and triple sox7, sox18, rbpj MO knockdown (Fig. 5 and Fig. S8 ). The expression of flt4 remained robust, indicating that venous identity was not compromised. However, we could find no detectable expression of any known arterial marker in triple sox7, sox18, rbpj embryos, including efnb2a, dlC, notch1b, flt1, notch1b, notch3 and hey2 (grl) (Fig. 5 C-E, Fig. S8 A-D) . notch3 expression was also absent after rbpj MO alone and is likely a direct Notch signaling Table S1 . Fig. 4 . Combinatorial knockdown of sox7, sox18, and rbpj in zebrafish results in ablation of both Dll4in3:GFP and endogenous dll4 expression. (A) Analysis of GFP expression in scrambled, rbpj, double sox7;sox18, and triple sox7;sox18;rbpj MO-injected tg(Dll4in3:GFP) embryos at 34 hpf. (B) Analysis of endogenous dll4 gene expression in scrambled, rbpj, double sox7;sox18, and triple sox7;sox18;rbpj MO-injected WT zebrafish embryos at 26 hpf. dll4 expression was detected by in situ hybridization. Values on the bottom right indicate number of embryos with the predominant and displayed phenotype per total number of embryos analyzed. In all cases, 0.125 pmol of sox7 and sox18 and 0.15 pmol of rbpj MO were used. *, highlights ectopic neural expression; arrowhead shows dorsal aorta. See also Fig. S6 .
target as previously reported (10) whereas other markers were absent only in the triple sox7, sox18, rbpj MO embryos. This total loss of arterial markers was unprecedented and suggests that combinatorial loss of sox7, sox18, and rbpj expression results in the inhibition of the entire early arterial gene expression program. These results are notably more severe than those seen after dll4 knockdown (Fig. S8 E-K) . Overall, the data presented here suggest that SoxF and Notch signaling controls arterial gene expression beyond the regulation of the Dll4 gene, revealing a combinatorial SoxF/Notch transcriptional code for arteriogenesis.
Discussion
Collectively, our data provide evidence supporting essential roles for SoxF and Notch, together, in the acquisition of arterial identity. It has been hypothesized that Notch signaling acquires specificity through the formation of transcriptional complexes with other, more specific factors. However, while the respective expression patterns of SoxF and Notch factors mean that they overlap in only the arterial compartment of the vasculature, potentially providing the required specificity, our data do not necessarily support the idea of a SoxF/Notch transcriptional complex. Dll4 expression occurs to some extent in the absence of direct binding of either SOXF or RBPJ, albeit at reduced levels. Although it is possible that SOXF and RBPJ binding was not completely ablated in the Dll4 mutant transgenes, due to cryptic binding sites elsewhere in the enhancers, the silencing of the transgene after combined RBPJ/SOX site mutations and the similarity of these results to the morphant fish suggest otherwise. Although RBPJ, NICD, and SOXF may form a transcriptional complex that requires only one factor to directly bind DNA, neither knockdown of sox7;sox18 and rbpj separately, nor chemical inhibition of the Notch pathway, mimics the severe arteriogenesis phenotype seen in the triple morphant fish, agreeing with previous reports that SOXF regulation occurs through a Notch-independent pathway (6). These results suggest that some degree of arterial identity can be acquired downstream of either Notch or SoxF, such that only perturbation of both pathways results in the loss of arterial identity.
Despite the genetic data linking the VEGF and Notch signaling pathways, it is still not clear how these two pathways interact to drive arterial endothelial cell differentiation. Because the Dll4 ligand plays such an integral, dose-dependent role in Notch signaling in the vasculature, it is enticing to think that VEGF may be upstream of Notch in part via the regulation of SOXF factors. VEGF-induced SOXF expression in endothelial cells would consequently achieve low-level Dll4 activation, increasing Notch signaling in neighboring cells, and thus reinforcing Dll4 expression. It will therefore be fascinating to uncover the mechanisms by which VEGF may regulate SOXF transcriptional activation.
The abnormal vascular remodeling and arterio-venous differentiation seen in β-catenin mutant embryos resemble that seen after modulation of Notch signaling and have been attributed to direct targeting of β-catenin to the Dll4 promoter through a TCF binding site (28) . β-catenin can also form an activation complex with NICD and RBPJ at a binding motif in the Dll4 third intron (here known as Dll4in3 RBPJ-a) (29) . Although our data demonstrate that both this motif and the promoter are dispensable for arterial Dll4 expression, β-catenin is also known to interact with SOXF proteins to regulate gene expression in a TCFindependent manner (30) . It is consequently likely that β-catenin may regulate Dll4 expression patterns in combination with, or upstream of, both RBPJ and SOXF factors. Previous studies have also proposed FOXC transcription factors as key regulators of arterial identity, at least in part through direct transcriptional activation of the Dll4 gene promoter (23) . However, the two Dll4 enhancers identified here work independently of the FOXCbinding endogenous promoter and contain no functional Forkhead binding motifs, suggesting that FOXC factors influence arterial development independently of Dll4 transactivation during early development. Our data indicate that other components of the Notch pathway, in addition to other arterial-specific genes including the VEGF receptor flt1 and the ephrin ligand efnB2a, are also downstream of the combinatorial SoxF/Notch code. Conversely, triple sox7:sox18:rbpj MO-injection had no effect on angioblast migration and midline coalescence, or pan-vascular gene expression. This suggests that the SoxF/Notch code is not required for early endothelial cell specification, and appears strikingly different from the vascular regulation directed by the Ets family of transcription factors. Loss of ETS factors in both mouse and fish disrupts early endothelial cell specification, and ETS binding motifs are found in all endothelial-expressed gene enhancers, regardless of expression pattern (17, 18) . These observations suggest that ETS factors regulate gene expression during early endothelial cell specification, other transcription factors, including Sox and NotchICD/Rbpj, contribute more precise spatial and temporal control of gene expression within the differentiating vasculature. The study of additional arterial-and venousspecific enhancers will therefore likely reveal further information about the transcriptional cascades regulating vascular patterning.
Materials and Methods
Cloning. Dll4in3, Dll4-12, and zfishDll4in3 enhancers were generated by PCR from BAC clone RP23-46P4 (CHORI) and genomic DNA respectively. Reporter vectors were generated using Gateway technology (Invitrogen). For Dll4i-n3end, Dll4in3 was cloned into pAUG-βGal upstream of the Dll4 promoter using SacII-NotI and SpeI-BamHI sites respectively. All mutated versions of Dll4in3 were generated by PCR (sequences in SI Materials and Methods).
Transgenic Animals. Transgenic mice were generated by oocyte microinjection. All animal procedures were approved by local ethical review and licensed by the UK Home Office. Analysis was performed as described previously, with care taken to ensure all embryos were consistently treated (31) . Mosaic transient transgenic zebrafish embryos were generated using the Tol2 system, and scored for GFP reporter expression at 24 hpf (32). The tg (Dll4in3:GFP) stable line was created by initial outcross of adult F0 carriers generated using the Tol2 system. The tg(fli1a:GFP), tg(kdrl:GFP) and tg (gata1:dsRed) lines were described previously (26, 33, 34) .
Morpholinos and Chemical Treatments. Antisense morpholino oligonucleotides were as described previously (4, 25) . MOs were injected into 1-to 2-cell wild-type or tg(Dll4in3:GFP) embryos, using 0.5 nL of the corresponding MO solution at a concentration depicted in figure legends. For pharmacological inhibition of VEGF and Notch signaling pathways, embryos were manually dechorionated and incubated with 1 μM of SU5416 (Sigma) or 100 μM DAPM (Calbiochem), respectively, starting at 10 hpf.
In Situ Hybridization and Immunohistochemistry. In situ hybridization and immunohistochemistry were performed as previously described (31, 35) .
ChIP. ChIP assays were performed on confluent HUVECS as described (36) using antibodies against Sox7, Sox18, Pol II (Santa Cruz), NICD1, RbpJ, and IgG (Abcam).
EMSA. EMSAs were performed as described previously (31) .
See SI Materials and Methods for additional details.
